These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 1496546)
21. Recognition and killing of tumour cells expressing heat shock protein 65 kD with immunotoxins containing saporin. Poccia F; Piselli P; Di Cesare S; Bach S; Colizzi V; Mattei M; Bolognesi A; Stirpe F Br J Cancer; 1992 Sep; 66(3):427-32. PubMed ID: 1520580 [TBL] [Abstract][Full Text] [Related]
22. Immunotoxins containing saporin 6 and monoclonal antibodies recognizing plasma cell-associated antigens: effects on target cells and on normal myeloid precursors (CFU-GM). Barbieri L; Dinota A; Gobbi M; Tazzari PL; Rizzi S; Bontadini A; Lemoli RM; Tura S; Stirpe F Eur J Haematol; 1989 Mar; 42(3):238-45. PubMed ID: 2784390 [TBL] [Abstract][Full Text] [Related]
23. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin. Urch CE; George AJ; Stevenson GT; Bolognesi A; Stirpe F; Weller R; Glennie MJ Int J Cancer; 1991 Apr; 47(6):909-15. PubMed ID: 2010234 [TBL] [Abstract][Full Text] [Related]
24. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates. Letvin NL; Goldmacher VS; Ritz J; Yetz JM; Schlossman SF; Lambert JM J Clin Invest; 1986 Mar; 77(3):977-84. PubMed ID: 3081579 [TBL] [Abstract][Full Text] [Related]
25. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. Delivery of ribosome-inactivating proteins to spleen and lymph node T cells. Letvin NL; Chalifoux LV; Reimann KA; Ritz J; Schlossman SF; Lambert JM J Clin Invest; 1986 Sep; 78(3):666-73. PubMed ID: 3489008 [TBL] [Abstract][Full Text] [Related]
26. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours. Flavell DJ; Flavell SU; Boehm DA; Emery L; Noss A; Ling NR; Richardson PR; Hardie D; Wright DH Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647 [TBL] [Abstract][Full Text] [Related]
27. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors. Cazzola M; Bergamaschi G; Dezza L; D'Uva R; Ponchio L; Rosti V; Ascari E Cancer Res; 1991 Jan; 51(2):536-41. PubMed ID: 1985771 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice. Morland BJ; Barley J; Boehm D; Flavell SU; Ghaleb N; Kohler JA; Okayama K; Wilkins B; Flavell DJ Br J Cancer; 1994 Feb; 69(2):279-85. PubMed ID: 7507691 [TBL] [Abstract][Full Text] [Related]
29. In vivo and in vitro uptake of an anti-CD30/saporin immunotoxin by rat liver parenchymal and nonparenchymal cells. Battelli MG; Buonamici L; Bolognesi A; Stirpe F Hepatology; 1994 Oct; 20(4 Pt 1):940-7. PubMed ID: 7927236 [TBL] [Abstract][Full Text] [Related]
30. Basic fibroblast growth factor-saporin mitotoxin. In vitro studies of its cell-killing activity and of substances that alter that activity. Martineau D; Lappi DA; Amburn E; Baird A Ann N Y Acad Sci; 1991; 638():438-41. PubMed ID: 1785818 [No Abstract] [Full Text] [Related]
31. Neuronotoxic effects of monoclonal anti-Thy 1 antibody (OX7) coupled to the ribosome inactivating protein, saporin, as studied by suicide transport experiments in the rat. Wiley RG; Stirpe F; Thorpe P; Oeltmann TN Brain Res; 1989 Dec; 505(1):44-54. PubMed ID: 2575436 [TBL] [Abstract][Full Text] [Related]
32. Immunological properties of ribosome-inactivating proteins and a saporin immunotoxin. Strocchi P; Barbieri L; Stirpe F J Immunol Methods; 1992 Oct; 155(1):57-63. PubMed ID: 1401966 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of antihuman T lymphocyte saporin immunotoxins potentially useful in human transplantation. Siena S; Bregni M; Formosa A; Martineau D; Lappi DA; Bonadonna G; Gianni AM Transplantation; 1988 Nov; 46(5):747-53. PubMed ID: 3264092 [TBL] [Abstract][Full Text] [Related]
35. Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line. Flavell DJ; Cooper S; Morland B; Flavell SU Br J Cancer; 1991 Aug; 64(2):274-80. PubMed ID: 1716453 [TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo properties of an anti-CD5-momordin immunotoxin on normal and neoplastic T lymphocytes. Porro G; Bolognesi A; Caretto P; Gromo G; Lento P; Mistza G; Sciumbata T; Stirpe F; Modena D Cancer Immunol Immunother; 1993 May; 36(5):346-50. PubMed ID: 7682894 [TBL] [Abstract][Full Text] [Related]
37. Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules. Flavell DJ; Cooper S; Morland B; French R; Flavell SU Br J Cancer; 1992 Apr; 65(4):545-51. PubMed ID: 1373293 [TBL] [Abstract][Full Text] [Related]
38. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia. Uckun FM; Chelstrom LM; Irvin JD; Finnegan D; Gunther R; Young J; Kuebelbeck V; Myers DE; Houston LL Blood; 1992 May; 79(10):2649-61. PubMed ID: 1375109 [TBL] [Abstract][Full Text] [Related]
39. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Pasqualucci L; Wasik M; Teicher BA; Flenghi L; Bolognesi A; Stirpe F; Polito L; Falini B; Kadin ME Blood; 1995 Apr; 85(8):2139-46. PubMed ID: 7718885 [TBL] [Abstract][Full Text] [Related]
40. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone. Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]